Serum 25-hydroxyvitamin D3 and D2 and non-clinical psychotic experiences in childhood by Tolppanen, AM et al.
Serum 25-Hydroxyvitamin D3 and D2 and Non-Clinical
Psychotic Experiences in Childhood
Anna-Maija Tolppanen1, Adrian Sayers2, William D. Fraser3, Glyn Lewis2, Stanley Zammit2,4,
John McGrath5, Debbie A. Lawlor1*
1MRC Centre for Causal Analyses in Translational Epidemiology, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom, 2 School of
Social and Community Medicine, University of Bristol, Bristol, United Kingdom, 3Norwich Medical School, University of East Anglia, Norwich, United Kingdom, 4MRC
Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, United Kingdom, 5Queensland Centre for Mental Health Research and Department of
Psychiatry and Queensland Brain Institute, University of Queensland, St Lucia, Australia
Abstract
Objective: Non-clinical psychotic experiences are common and distressing. It has been hypothesized that early life vitamin
D deficiency may be a risk factor for psychosis-related outcomes, but it is not known if circulating concentrations of 25-
hydroxyvitamin D (25(OH)D) during childhood are associated with psychosis-related outcomes or whether the two different
forms of 25(OH)D, (25(OH)D3 and 25(OH)D2, have similar associations with psychosis-related outcomes.
Methods: We investigated the association between serum 25(OH)D3 and 25(OH)D2 concentrations and psychotic
experiences in a prospective birth cohort study. Serum 25(OH)D3 and 25(OH)D2 concentrations were measured at mean age
9.8 years and psychotic experiences assessed at mean age 12.8 years by a psychologist (N = 3182).
Results: Higher 25(OH)D3 concentrations were associated with lower risk of definite psychotic experiences (adjusted odds
ratio: OR (95% confidence interval: CI) 0.85 (0.75–0.95)). Higher concentrations of 25(OH)D2 were associated with higher risk
of suspected and definite psychotic experiences (adjusted odds ratio: OR (95% confidence interval: CI) 1.26 (1.11, 1.43)).
Higher 25(OD)D2 concentrations were also weakly associated with definite psychotic experiences (adjusted OR (95% CI) 1.17
(0.96, 1.43), though with wide confidence intervals including the null value.
Conclusions: Our findings of an inverse association of 25(OH)D3 with definite psychotic experiences is consistent with the
hypothesis that vitamin D may protect against psychosis-related outcomes.
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Introduction
Non-clinical psychotic experiences occur in approximately 10%
of the population and people experiencing such symptoms may be
at higher risk of clinical psychotic disorders later in life. [1–3] If
a substantial proportion of individuals in non-clinical samples have
psychotic experiences occurring as a result of pathological
abnormalities underlying the etiology of schizophrenia, we might
expect shared risk factors for both phenotypes. [4] Low vitamin D
status during early life has been suggested to be a risk factor for
schizophrenia. [5] Previous studies have assessed associations
between serum 25-hydroxyvitamin D (25(OH)D) measured from
neonatal blood samples [6] or vitamin D supplementation during
first year of life [7] and later risk of schizophrenia. However, it is
unknown if serum 25(OH)D concentrations in childhood are
associated with psychotic experiences. The only previous study
that we are aware of, examining the association of vitamin D and
psychotic experiences, was a cross-sectional study of adults,
examining the association of dietary intake of vitamin D. [8]
Serum 25(OH)D concentrations are mainly determined by
ultraviolet B (UVB) exposure and therefore the possibility that
individuals with psychotic experiences were less likely to eat diets
rich in vitamin D (rather than the dietary vitamin D affecting
psychotic experiences) cannot be excluded.
25(OH)D consists of (a) 25(OH)D3 (synthesised from vitamin D3
mainly obtained from synthesis in skin in response to UVB
exposure, but also from supplements and some food sources such
as oily fish) and (b) 25(OH)D2 (synthesised from vitamin D2 which
is obtained from plant food sources and supplements). It is
valuable to examine the associations of both forms of 25(OH)D
with outcomes, because supplements of either vitamin D2 or D3
are readily available and if it is found that circulating concentra-
tion of one form is more strongly associated with outcomes than
the other, and this is subsequently determined to be causal, then
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future trials of effectiveness of supplementation should use the one
with the likely stronger effect. To our knowledge previous studies
have not examined the association between 25(OH)D2 concentra-
tions and cognitive outcomes or whether 25(OH)D3 and
25(OH)D2 differ from each other in their associations with
psychotic experiences. The aims of this study were to investigate
the prospective associations of 25(OH)D3 and 25(OH)D2 with
non-clinical psychotic experiences and to compare the magnitudes
of association of the two forms of 25(OH)D with each other.
Because vitamin D, together with parathyroid hormone (PTH)
regulates calcium and phosphate homeostasis [9,10] we in-
vestigated whether PTH, calcium and phosphate were associated
with psychotic experiences and whether the associations of
25(OH)D3 or 25(OH)D2 were independent of PTH, calcium or
phosphate concentrations.
Methods
Population
The Avon Longitudinal Study of Parents and Children
(ALSPAC) is a population-based birth cohort from South West
England. The cohort consisted of 14062 live births from 14541
enrolled pregnant women who were expected to give birth
between April 1, 1991, and December 31, 1992. [11] From age 7,
all children were invited for an annual assessment of physical and
psychological development. Parents gave informed consent and
ethical approval was obtained from the ALSPAC Law and Ethics
Research Committee and the National Health Service local
research ethics committee.
Single and twin births were included in this study; the very small
number of triplets and quadruplets were not included for reasons
of confidentiality. Figure 1 shows the flow of participants through
the cohort follow-up and numbers available for analyses. In this
study we included 3182 participants with complete data on
exposures, outcome and co-variables.
Exposures and Blood Based co-variables
Serum 25(OH)D3, 25(OH)D2, PTH, phosphate and calcium
were assayed on non-fasting blood samples collected at mean age
9.9 years for the majority of participants. If no samples were
available from the 9.9 years assessment, samples from mean age
11.8 years or, secondly, the 7.6 years assessment, were used. The
mean age at sample collection in the whole study sample was 9.8
years (standard deviation: SD 1.1). After the phlebotomy, the
samples were immediately frozen at 280uC in freezers temper-
ature control and electronic temperature monitoring. Assays were
performed in 2010 after a maximum of 12 years in storage at
280uC with no previous freeze-thaw cycles. 25(OH)D2,
25(OH)D3 and deuterated internal standard were extracted from
serum samples after protein precipitation using zinc sulphate with
Isolute C18 solid phase extraction cartridges (Biotage AB,
Uppsala, Sweden). Potential interfering compounds were removed
by initial elution with 50% methanol followed by elution of the
vitamins using 10% tetrahydrofuran in acetonitrile. Dried extracts
were reconstituted prior to injection into a high performance
liquid chromatography tandem mass spectrometer including
Waters 2777 autosampler (Waters Acquity, Manchester UK) in
conjunction with a Knauer Smartline 1000 quaternary pump and
6300 Sample preparation unit (Knauer, Berlin, Germany), fitted
with Knauer 10 mm C18 guard column Waters Sunfire 3.5 mm
2.1 mm650 mm C18 column and Micromass Quattro Ultima
Platinum (KRSS, Manchester, UK) fitted with a Z Spray
electrospray ionisation inlet. The following mass to charge ratios
in the multiple reaction mode were used: 413.2.395.3,
401.1.383.3 and, 407.5.107.2 for 25(OH)D2, 25(OH)D3, and
deuterated internal standard, respectively. Inter-assay coefficients
of variation (CV) for the assay were ,10% across a working range
of 1–250 ng/mL for both 25(OH)D3 and 25(OH)D2. The
sensitivities of the assays were defined by estimating the signal to
noise ratio obtained at low 25(OH)D2 and 25(OH)D3 concentra-
tions. Measurements were performed in the Bioanalytical Facility
of Royal Liverpool University Hospital laboratory which meets the
performance target set by the Vitamin D External Quality
Assessment Scheme (DEQAS) Advisory Panel for 25(OH)D
assays.
Total serum calcium, phosphate and albumin concentrations
were measured by standard laboratory methods on Roche
Modular analysers (Roche Diagnostics Ltd, West Sussex, UK).
Serum calcium was adjusted for albumin using a normogram of
calcium and albumin distributions of the samples analysed in the
clinical chemistry laboratory where the measurements were
performed. Intact parathyroid hormone (iPTH(1–84)) was mea-
sured by electrochemiluminescent immunoassay on an Elecsys
2010 immunoanalyzer (Roche, Lewes, UK). Inter-assay CV was
,6% from 2–50 pmol/L. The assay sensitivity (22% CV for
duplicates) was 1 pmol/L.
Outcomes
Psychotic experiences were assessed using the semi-structured
psychosis-like symptoms (PLIKS) interview administered by
trained psychologists at mean (SD) age of 12.8 (0.2) years as
described previously. [12] Semi-structured interviews are most
closely approximated to clinical assessments of psychotic phenom-
ena in clinical psychiatry as they allow for cross-examination of
individuals to ensure that the experiences described are psychotic
phenomena, unlike self-report assessments and structured inter-
views that over-estimate the occurrence of such experiences.
[13,14] The PLIKS interview asks about the occurrence of visual
and auditory hallucinations, delusions and experiences of thought
interference during the previous 6-months. Twelve core items
were probed with stem questions derived from the Diagnostic
Interview Schedule for Children version IV [15] and the
Schedules for Clinical Assessment in Neuropsychiatry version
2.0. [16] These were modified slightly after piloting [further details
available at Academic Unit of Psychiatry, University of Bristol
(http://www.bristol.ac.uk/psychiatry/staff/zammit/documents/
pliks.pdf)]. Interviewers rated symptoms as not present/suspected/
definitely present. Symptoms were included only if they were not
attributable to effects of sleep or fever and were rated as definite
only when a credible example was provided. The average kappa
value for interrater reliability within our study was 0.72. [14].
Confounding Factors
We considered gender, age, ethnicity (white/non-white), socio-
economic position, family history of depression or schizophrenia,
exposure to UVB, body mass index (BMI), cognitive function and
puberty stage to be potential confounders because of their known
associations with 25(OH)D concentrations and psychotic experi-
ences. Thus, we defined confounders as common causes of
exposure and outcome and based the selection on existing
literature, as suggested by Herna´n et al, [17] instead of using any
arbitrary statistical criteria. Data on head of household social class,
ethnicity, maternal and paternal education and family history of
depression, schizophrenia or other psychiatric problem were
obtained from parent-completed questionnaires. Data on time
spent outdoors and protection from solar UVB exposure (use of
sunblock, covering clothing or hat and avoidance of midday sun)
was obtained from parent-completed questionnaires at mean age
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of 8.5 years. BMI was calculated from height and weight measured
at the same time as blood samples were taken. Total IQ score in
Wechsler Intelligence Scale for Children (WISC-III UK version)
was assessed at mean age 8.5. Puberty stage was assessed by
parental report using Tanner staging [18] of breast development
and pubic hair on repeat occasions. We used data from the
questionnaire closest to the time of phlebotomy.
Statistical Analysis
Statistical analyses were conducted with Stata 11.0 (Stata Corp
LP, College Station, TX USA).
25(OH)D3 concentrations followed sinusoidal seasonal variation
with peaks during summer and troughs during winter (Figure 2).
Therefore 25(OH)D3 was modeled according to date of blood
sampling using linear regression with trigonometric sine and
cosine functions. 25(OH)D3 was loge transformed to reduce
heteroscedasticity. The residual was then used as 25(OH)D3
exposure variable in regression analyses. To include all partici-
pants on whom 25(OH)D2 was assayed, those with a value below
the detectable limit of the assay (0.5 ng/mL) were given a value of
0.5 ng/mL and indicated using a binary covariable in all
regression models (n = 1129, 35.5%). For the main analyses we
compared associations of seasonal adjusted 25(OH)D3 with
psychotic experiences to those of 25(OH)D2 and also present
associations of total 25(OH)D with outcomes for better compara-
bility across studies. In supplementary analyses we also report
associations unadjusted (for season) 25(OH)D3 with psychotic
experiences. This examines whether adjustment for season change
explains any of the association. In order to take account of age
differences at the time of assessment we generated age- and
gender-standardised standard deviation scores for serum
Figure 1. Flow of participants.
doi:10.1371/journal.pone.0041575.g001
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25(OH)D3, 25(OH)D2, calcium, phosphate and PTH using the
internal cohort data with age in one month categories.
The associations of potential confounders with age- and gender-
standardised 25(OH)D3, 25(OH)D2, calcium, phosphate and PTH
concentrations was assessed with linear regression and the
associations of confounders with psychotic experiences with
logistic regression. To examine the main associations of interest
of exposures with outcome and to compare associations of
different exposures we performed a non-parametric bootstrap
procedure in conjunction with multivariable logistic regression,
based on 1000 replications. The bootstrapping procedure enabled
us to statistically compare associations of 25(OH)D3 with psychotic
experiences to those of 25(OH)D2 with psychotic experiences. The
difference between the association of 25(OH)D3 and 25(OH)D2
was calculated from the bootstrap replicate distribution. Beta
estimates and standard errors were empirically calculated from the
mean and standard deviation of the bootstrap distribution,
respectively. All P values were calculated using bootstrap means
and standard errors and compared to a z-distribution.
We examined two outcomes: a combined outcome of both
suspected or definite psychotic experiences versus none, and
definite psychotic experiences versus none (i.e. in the latter those
with suspected psychotic experiences were removed from the
analyses). To numerically compare the associations of two forms of
25(OH)D, beta coefficients from the logistic regression models
were multiplied by loge(2). The results are interpreted as the odds
ratio of psychotic experiences (suspected or definite versus none or
definite versus none) per doubling of exposure. Linearity of
associations was tested with a likelihood ratio test comparing
a model with quintiles of standardized exposure as indicator
variables to model with exposure quintiles as a continuous score.
Results
The median (interquartile range) for unadjusted 25(OH)D3,
seasonal adjusted 25(OH)D3, 25(OH)D2 and total 25(OH)D in the
analysis sample (N=3182) were 22.2 (17.4–27.5), 24.9 (24.7–25.1),
1.3 (0.5–2.7) and 24.1 (19.4–29.4) ng/mL, respectively. The
median (interquartile range) for serum phosphate, albumin-
adjusted calcium and PTH were 1.53 (1.43–1.64) mmol/L, 2.37
(2.31–2.45) mmol/L and 4.5 (3.4–5.8) pmol/L, respectively.
Distribution of 25(OH)D2 concentrations was positively skewed,
while 25(OH)D3 concentration was approximately normally
distributed; as noted above both were log transformed for the
analyses. The proportion of participants with total 25(OH)D
concentration below 20 ng/mL was similar among all 7560
participants with serum measurements (n = 2162, 28.6%) and
among the 3182 participants included in this study (n= 896,
28.2%). In the analysis cohort of 3182 participants, 350 (11.0%)
had the combined outcome of suspected or definite psychotic
experiences and 142 (4.8%) had definite psychotic experiences;
these proportions were similar to those in the total 6440
participants who provided data on psychotic experiences (some
of whom were excluded because of missing exposure or covariable
data): 742 (11.5%) had suspected or definite psychotic experiences
and 300 (4.7%) had definite psychotic experiences.
Table S1 shows the univariable associations of potential
confounders with 25(OH)D2 and 25(OH)D3 and the associations
of potential confounders with PTH, calcium and phosphate are
shown in Table S2. Higher BMI and non-white ethnicity were
associated with lower 25(OH)D2 concentrations and higher PTH
concentrations. White children had higher 25(OH)D3 and lower
PTH concentrations. Children from higher socioeconomic back-
grounds had higher 25(OH)D3 and lower 25(OH)D2 and calcium
Figure 2. Seasonal variation in serum 25(OH)D3 concentrations. Dots represent individual observations and the average seasonal value is
indicated by the line.
doi:10.1371/journal.pone.0041575.g002
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concentrations. Those who avoided midday sun more often had
lower concentrations of 25(OH)D3 and calcium and higher
concentrations of phosphate and 25(OH)D2. Children who spent
less time outdoors in the summer had lower 25(OH)D3
concentrations.
Table S3 shows the univariable associations of potential
confounders with psychotic experiences. Children with higher
IQ and those with white ethnicity were less likely to have
experienced definite psychotic experiences. Lower parental
education and parental history of mental health problems were
associated with higher risk of suspected/definite and definite
psychotic experiences. Children who spent more time outdoors
during summer weekends were slightly more likely to have
suspected/definite and definite psychotic experiences.
Table 1 shows the multivariable associations between exposures
and psychotic experiences. Serum 25(OH)D3 concentrations were
inversely associated with definite psychotic experiences in analyses
that controlled for age, gender, season and ethnicity (Model 1).
The association remained similar after adjusting for outdoor
exposure and BMI (Model 2), socioeconomic position, family
history of mental health problems and IQ (Model 3) and other
analytes including 25(OH)D2 (Model 4). This association appeared
linear across the entire distribution of 25(OH)D3 (P for evidence of
non-linearity = 0.64). When the outcome was extended to include
both suspected as well as definite psychotic experiences there was
no clear association of 25(OH)D3 with this outcome.
Higher serum 25(OH)D2 concentrations were positively associ-
ated with definite psychotic experiences in all models, but the
estimates were imprecise and 95% confidence intervals included
the null value. When the outcomes were extended to include both
suspected and definite cases there was a statistically robust
association in all models, which appeared linear across the
distribution of 25(OH)D2 (P for evidence of a non-linear
association = 0.18).
There was strong statistical evidence that the inverse association
of 25(OH)D3 with definite psychotic experiences differed from the
positive association of 25(OH)D2 association with this outcome
(P= 0.008). There was also evidence that the associations of
25(OH)D3 and 25(OH)D2 with suspected/definite psychotic
experiences statistically differed from each other (P=0.005).
Associations of total 25 (OH) D with outcomes were broadly
similar to those seen with 25(OH)D3 (Table 1). None of PTH,
calcium or phosphate concentrations were associated with
psychotic experiences (Table 1) and hence there was no evidence
that these mediated any of the observed associations of total
25(OH)D, 25(OH)D3 or 25(OH)D2 with outcomes (Model 4 in
Table 1).
The associations of unadjusted (for season) 25(OH)D3 (Table 2)
were broadly similar to those of seasonal adjusted 25(OH)D3.
Discussion
Consistent with the hypothesis that better vitamin D status,
indicated by higher concentrations of 25(OH)D, protects against
schizophrenia we found an inverse association of serum concen-
trations of 25(OH)D3 and total 25(OH)D with definite psychotic
experiences in childhood, though the association was weaker when
suspected cases were also included in the outcome. Contrary to
expectations from previous studies of total 25(OH)D or those of
dietary or supplement intake of vitamin D with schizophrenia, we
found that higher concentrations of 25(OH)D2 were associated
with psychotic experiences. However, it should be noted that the
results are presented per doubling of exposure and thus the
associations of 25(OH)D3 and 25(OH)D2 (15% risk decrease and
26%risk increase in the adjusted model, respectively) were modest.
The associations were robust to adjustment for a range of
potential confounding factors that we selected based on appropri-
ate methods. [17] Decisions regarding such selection can be
difficult, e.g. with 25(OH)D3 adjustment for seasonality and UVB
Table 1. Prospective association of seasonal adjusted 25(OH)D3, 25(OH)D2, phosphate, calcium and PTH concentrations (assessed
at mean age 9.9 years) with psychotic experiences (PLIKS) (assessed at age 12.8 years).
Exposure Outcome Odds ratio of outcome per doubling of exposure (95%CI)
Model 1 Model 2 Model 3 Model 4
25(OH)D3 Suspected/definite PLIKS 0.95 (0.88, 1.02) 0.94 (0.87, 1.01) 0.95 (0.88, 1.03) 0.96 (0.88, 1.03)
Definite PLIKS 0.86 (0.77, 0.95) 0.85 (0.75, 0.95) 0.85 (0.76, 0.95) 0.85 (0.75, 0.95)
25(OH)D2 Suspected/definite PLIKS 1.27 (1.13, 1.43) 1.27 (1.11, 1.44) 1.26 (1.12, 1.43) 1.26 (1.11, 1.43)
Definite PLIKS 1.21 (1.00, 1.48) 1.21 (0.98, 1.47) 1.19 (0.98, 1.43) 1.17 (0.96, 1.43)
Total 25(OH)D Suspected/definite PLIKS 0.95 (0.89, 1.03) 0.95 (0.88, 1.02) 0.95 (0.88, 1.02) 0.95 (0.88, 1.03)
Definite PLIKS 0.90 (0.82, 1.00) 0.89 (0.81, 0.98) 0.89 (0.80, 0.99) 0.89 (0.80, 0.99)
Albumin-adjusted calcium Suspected/definite PLIKS 1.04 (0.95, 1.12) 1.04 (0.96, 1.13) 1.03 (0.95, 1.12) 1.01 (0.93, 1.09)
Definite PLIKS 1.05 (0.92, 1.19) 1.05 (0.92, 1.18) 1.05 (0.92, 1.19) 1.05 (0.91, 1.21)
Phosphate Suspected/definite PLIKS 1.05 (0.97, 1.13) 1.05 (0.98, 1.13) 1.06 (0.98, 1.15) 1.05 (0.96, 1.14)
Definite PLIKS 0.98 (0.89, 1.09) 0.99 (0.89, 1.10) 0.99 (0.88, 1.12) 0.97 (0.87, 1.09)
Parathyroid hormone Suspected/definite PLIKS 1.02 (0.94, 1.11) 1.02 (0.94, 1.11) 1.02 (0.93, 1.11) 1.00 (0.91, 1.10)
Definite PLIKS 1.02 (0.91, 1.13) 1.03 (0.92, 1.15) 1.03 (0.92, 1.15) 1.01 (0.89, 1.15)
N= 3182 (208 cases with suspected/definite PLIKS) and N=2974 (142 cases with definite PLIKS; in these analyses suspected cases are removed from the analyses).
Model 1 is unadjusted (all exposures are standardised for age and gender and 25(OH)D3 is adjusted for season and ethnicity).
Model 2 as Model 1 plus adjustment for ethnicity, time spent outdoors during summer (age 8.5 years), use of sunblock, hat, covering clothing, avoidance of midday sun
and BMI.
Model 3 as Model 2 plus adjustment for head of household social class, mother’s and partner’s education, family history of mental health problems and puberty stage.
Model 4 as Model 3 plus adjustment for serum concentrations of other hormones/metabolites which are related to vitamin D homeostasis (i.e. each of the exposures
listed in the first column is mutually adjusted for all others in the first column).
doi:10.1371/journal.pone.0041575.t001
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exposure might be considered as overadjustment, given their role
in determining 25(OH)D3. However, the associations were similar
when we used 25(OH)D3 without adjustment for seasonality
(Table S2) and also when we removed indicators of UVB exposure
(data not presented). Adjustment for seasonality in studies assessing
the association of 25(OH)D with outcomes can improve statistical
efficiency and reduce confounding when the outcome is also likely
to be seasonally patterned and does not lead to overadjustment.
[19] There has been debate about whether BMI or adiposity
influences 25(OH)D concentrations or the other way around (i.e.
25(OH)D influences adiposity. A recent Mendelian randomization
study supports the direction being form greater adiposity causing
lower 25(OH)D, [20] than the other way round, which supports
inclusion of BMI as a potential confounder.
To our knowledge one previous study has examined the
association of vitamin D with psychotic experiences. [8] In that
large cross-sectional study of women, dietary vitamin D intake,
estimated with food frequency questionnaires, was inversely
associated with psychotic experiences. It is difficult to directly
compare these results with ours as we find the inverse association
only with 25(OH)D3, which is largely determined by UVB,
rather than diet. Another prospective study found that maternal
report of vitamin D supplementation in the first year of life was
protective against schizophrenia in adulthood in men but not in
women. [7] Since the exposure in that cohort study was maternal
report of vitamin D3 and/or D2 supplement use with no detailed
data on which supplement the children received, [21] it is
impossible to know whether that represented predominantly an
association of vitamin D3 or D2 with outcome. Notably, in these
previous studies the outcome was assessed in adulthood, [7,8]
while we studied the association with psychotic experiences in
childhood/early adolescence.
We had the opportunity to explore the relative associations of
both 25(OH)D3 and 25(OH)D2 with psychotic experiences. This is
important because on the basis of associations with bone outcomes
[22,23] and affinity for vitamin D binding protein [23,24] it has
been suggested that vitamin D3 is more potent than vitamin D2
but nutritional supplements are available in both forms and for
non-bone outcomes any differences between the associations of
two forms of 25(OH)D are, as yet, unknown. We have previously
shown that although 25(OH)D3 was the major contributor to total
25(OH)D in this cohort, 25(OH)D2 makes an important contri-
bution to total 25(OH)D concentrations in some children,
especially those with low total 25(OH)D concentrations. [25].
Our data linking outdoor behaviour with 25(OH)D3 is
consistent with the hypothesis that the children in this cohort
largely received their vitamin D3 via sunlight exposure on the skin,
not dietary intake. While over a third of the cohort had no
detectable 25(OH)D2, it was of interest to note that those with
higher concentrations of this form of circulating 25(OH)D (which
is exclusively derived from dietary sources such as fortified
margarine and cereals as well as supplements) were more likely
to report psychotic experiences. This finding may be a chance
occurrence, given the lack of any previous studies with which to
compare the results. It could reflect residual confounding by one
or more characteristics that are related to increased dietary intake
of vitamin D2 and also increased risk of psychotic experiences. It
could be causal, but as yet we are unaware of any biological
mechanism that would explain it or different associations of
25(OH)D3 and 25(OH)D2. We emphasise that this finding should
be treated with caution unless replicated in other studies.
Experimental studies suggest that vitamin D is important for
neuronal function and brain development [26–29]. The majority
of the animal studies that have examined effects on neuronal
function have been based on vitamin D receptor knock-out models
or developmental vitamin D deficiency. The relevance of these
studies to our findings depends on the extent to which the
consequences of early life vitamin D deficiency in animal models,
including lateral ventricle size/structure, increased cellular pro-
liferation, reduced apoptosis, and altered neurogenesis [26–29]
continue to operate in children and adolescents. There is some
emerging evidence to suggest that low vitamin D status may
impact on brain outcomes differently in the post-natal brain (e.g.
vitamin D may be ‘neuroprotective’ and help the post-natal brain
cope with stressors). [30,31].
In interpreting our findings it is important to consider what
psychotic experiences reflect. If they represent an early expression
of pathological neurodevelopmental processes that later lead to
schizophrenia, our results would have potential implications for
predication and for understanding aetiology of schizophrenia. This
possibility is supported by suggestions that people with non-clinical
psychotic experiences represent a valuable and valid group for
studying the aetiology of clinical psychosis, and the similarity of
risk factors for non-clinical and clinical psychotic symptoms. [4]
However, it is also true that in many individuals who report
psychotic experiences, these phenomena are transient, and despite
the clear association between earlier psychotic experiences and
later clinical psychotic disorders, the majority of those with
psychotic experiences do not progress to clinical disorders.
[2,3,32,33] Even if such experiences are not a useful indicator of
future clinical outcomes, they are associated with distress and
functional impairment, [34,35] and may represent an important
public health concern, in the same way that symptoms of
depression and anxiety that do not reach thresholds used to
Table 2. Prospective association of unadjusted (for season) 25(OH)D3 concentrations (assessed at mean age 9.9 years) with
psychotic experiences (PLIKS) (assessed at age 12.8 years). N = 3182 (208 cases with suspected/definite PLIKS) and N= 2974 (142
cases with definite PLIKS; in these analyses suspected cases are removed from the analyses).
Exposure Outcome Odds ratio of outcome per doubling of exposure (95%CI)
Model 1 Model 2 Model 3 Model 4
25(OH)D3 Suspected/definite PLIKS 0.88 (0.79, 0.97) 0.87 (0.78, 0.96) 0.87 (0.77, 0.96) 0.88 (0.79, 0.98)
Definite PLIKS 0.88 (0.79, 0.97) 0.86 (0.78, 0.95) 0.87 (0.78, 0.95) 0.88 (0.78, 0.98)
Model 1 is unadjusted (25(OH)D3 is adjusted for age and gender).
Model 2 as Model 1 plus adjustment for ethnicity, time spent outdoors during summer (age 8.5 years), use of sunblock, hat, covering clothing, avoidance of midday sun
and BMI.
Model 3 as Model 2 plus adjustment for head of household social class, mother’s and partner’s education, family history of mental health problems and puberty stage.
Model 4 as Model 3 plus adjustment for 25(OH)D2, phosphate, albumin-adjusted calcium and parathyroid hormone.
doi:10.1371/journal.pone.0041575.t002
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formally diagnose depression do. [36] Thus, understanding more
about the aetiology of such experiences is likely to be important.
The study has several important limitations. We lacked
detailed information on supplement intake for the cohort
members and thus were not able to infer how much of the
circulatory 25(OH)D3 was derived from dietary sources.
Although we were able to adjust for confounders, including
measures of socioeconomic position and outdoor exposure, it is
possible that these dimensions were not fully captured and there
is some residual confounding. Reverse causality is possible, for
example if those with psychotic experiences were less likely to
go outdoors and be exposed to UVB as a result of these
symptoms. However, the prospective nature of our study
reduces this possibility and prospectively we actually found
a weak positive association of reported time spent outdoors with
psychotic experiences, making this possibility unlikely. Our
findings may be due to chance and thus further replication in
large prospective cohorts would be valuable, as would compar-
ing the associations of both forms of 25(OH)D with hard
endpoint of clinically diagnosed schizophrenia, in order to
establish the true association with this disorder. Mendelian
randomization studies, in which genetic variants that are
robustly associated with circulating concentrations of
25(OH)D3 and 25(OH)D2 are used as instrumental variables
to assess their causal effects on outcomes [37–39] would also be
valuable, but these would require very large sample sizes.
Ultimately, large randomised trials would be required to
determine whether supplementation with vitamin D was an
effective means of preventing psychosis-related outcomes. [40]
Our findings do suggest that vitamin D3 would be the more
appropriate supplement to be assessed in trials examining the
effect of this vitamin on psychotic experiences if these further
studies were to suggest causal protective effects of this form of
vitamin D.
We only used data from a single measurement of exposures
which may be inadequate, [41] although a single measurement
may be a useful biomarker of season-specific vitamin D status over
a longer time. [42]. Our sample included mainly white children
(the number of non-white children inthe main analyses was 84
(2.6%)), which may limit the generalisability of the results, but does
mean that residual confounding due to ethnicity is unlikely.
Similar to other prospective cohort studies there was loss to follow-
up and those who have attended follow-up clinics tend to be from
higher socioeconomic groups. [11] However, the prevalence of
psychotic experiences was similar in complete cases and those who
were excluded due to missing data.
Conclusions
In conclusion, our findings provide some support for an inverse
association of total 25(OH)D and 25(OH)D3 concentrations with
psychotic experiences, which if psychotic experiences are related to
development of schizophrenia, also support a possible protective
association of higher 25(OH)D3 concentrations with schizophre-
nia. The positive association of 25(OH)D2 concentrations with
psychotic experiences was unexpected and is currently un-
explained. Further replication of our findings in large prospective
studies would be valuable, as would the use of studies, such as
Mendelian randomized controlled trials and randomised con-
trolled trials, that are more able to establish whether associations
are likely to be causal or not.
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